142 related articles for article (PubMed ID: 26708191)
21. Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials.
Thomopoulos C; Skalis G; Michalopoulou H; Tsioufis C; Makris T
Clin Cardiol; 2015 Dec; 38(12):763-9. PubMed ID: 26282344
[TBL] [Abstract][Full Text] [Related]
22. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria.
Virani SS; Akeroyd JM; Nambi V; Maddox TM; Gillette MA; Michael Ho P; Rumsfeld J; Petersen LA; Ballantyne CM
Am J Med; 2015 Nov; 128(11):1253-6. PubMed ID: 26071828
[TBL] [Abstract][Full Text] [Related]
23. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease.
Zinellu A; Sotgia S; Mangoni AA; Sotgiu E; Ena S; Satta AE; Carru C
J Pharm Biomed Anal; 2016 Sep; 129():383-388. PubMed ID: 27454090
[TBL] [Abstract][Full Text] [Related]
24. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
Oyama K; Giugliano RP; Blazing MA; Park JG; Tershakovec AM; Sabatine MS; Cannon CP; Braunwald E
J Am Coll Cardiol; 2021 Oct; 78(15):1499-1507. PubMed ID: 34620406
[TBL] [Abstract][Full Text] [Related]
25. Considerations in Applying the Results of Randomized Controlled Clinical Trials to the Care of Older Adults With Kidney Disease in the Clinical Setting: The SHARP Trial.
Butler CR; O'Hare AM
Adv Chronic Kidney Dis; 2016 Jan; 23(1):29-35. PubMed ID: 26709060
[TBL] [Abstract][Full Text] [Related]
26. Effects of lipid-lowering treatment on circulating microparticles in patients with diabetes mellitus and chronic kidney disease.
Almquist T; Mobarrez F; Jacobson SH; Wallén H; Hjemdahl P
Nephrol Dial Transplant; 2016 Jun; 31(6):944-52. PubMed ID: 26394646
[TBL] [Abstract][Full Text] [Related]
27. Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study).
Bang CN; Greve AM; La Cour M; Boman K; Gohlke-Bärwolf C; Ray S; Pedersen T; Rossebø A; Okin PM; Devereux RB; Wachtell K
Am J Cardiol; 2015 Dec; 116(12):1840-4. PubMed ID: 26602073
[TBL] [Abstract][Full Text] [Related]
28. Effect of simvastatin and ezetimibe on suPAR levels and outcomes.
Hodges GW; Bang CN; Forman JL; Olsen MH; Boman K; Ray S; Kesäniemi YA; Eugen-Olsen J; Greve AM; Jeppesen JL; Wachtell K
Atherosclerosis; 2018 May; 272():129-136. PubMed ID: 29602140
[TBL] [Abstract][Full Text] [Related]
29. Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT).
Sharma A; Sun JL; Lokhnygina Y; Roe MT; Ahmad T; Desai NR; Blazing MA
Am J Cardiol; 2019 Apr; 123(8):1193-1201. PubMed ID: 30739657
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia.
Davidson MH
J Am Coll Cardiol; 2003 Jul; 42(2):398-9; author reply 399. PubMed ID: 12875794
[No Abstract] [Full Text] [Related]
31. Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.
Herrington W; Staplin N; Judge PK; Mafham M; Emberson J; Haynes R; Wheeler DC; Walker R; Tomson C; Agodoa L; Wiecek A; Lewington S; Reith CA; Landray MJ; Baigent C;
Hypertension; 2017 Feb; 69(2):314-322. PubMed ID: 28028192
[TBL] [Abstract][Full Text] [Related]
32. Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications.
Davidson MH
Cleve Clin J Med; 2008 Jul; 75(7):479-82, 486-8, 490-1. PubMed ID: 18646584
[No Abstract] [Full Text] [Related]
33. IMPROVE-IT: what have we learned?
Banach M; Nikolic D; Rizzo M; Toth PP
Curr Opin Cardiol; 2016 Jul; 31(4):426-33. PubMed ID: 27218683
[TBL] [Abstract][Full Text] [Related]
34. Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Response to: Toth PP, Davidson MH: simvastatin and ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin. Pharmacother. (2005) 6(1):131-139.
Ahmed MH; Saad RA; Osman MM
Expert Opin Drug Saf; 2006 Jul; 5(4):487-8. PubMed ID: 16774486
[No Abstract] [Full Text] [Related]
35. Effects of short-term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients.
Guimarães ES; Cerda A; Dorea EL; Bernik MMS; Gusukuma MC; Pinto GA; Fajardo CM; Hirata MH; Hirata RDC
Cardiovasc Ther; 2017 Dec; 35(6):. PubMed ID: 28940978
[TBL] [Abstract][Full Text] [Related]
36. Simvastatin with or without ezetimibe in familial hypercholesterolemia.
Diamond GA; Kaul S
N Engl J Med; 2008 Jul; 359(5):530; author reply 532. PubMed ID: 18677796
[No Abstract] [Full Text] [Related]
37. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
Sharp Collaborative Group
Am Heart J; 2010 Nov; 160(5):785-794.e10. PubMed ID: 21095263
[TBL] [Abstract][Full Text] [Related]
38. Ezetimibe combines with simvastatin to tackle cholesterol. New drugs attack "bad" cholesterol in the liver and intestine.
Heart Advis; 2007 Jul; 10(7):7. PubMed ID: 17695657
[No Abstract] [Full Text] [Related]
39. Relation of Lipid-Lowering Therapy to Need for Aortic Valve Replacement in Patients With Asymptomatic Mild to Moderate Aortic Stenosis.
Greve AM; Bang CN; Boman K; Egstrup K; Kesäniemi YA; Ray S; Pedersen TR; Wachtell K
Am J Cardiol; 2019 Dec; 124(11):1736-1740. PubMed ID: 31586530
[TBL] [Abstract][Full Text] [Related]
40. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Lancellotti P; Pierard LA; Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
